A5086631961- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Pancreatitis Pathology and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Gastrointestinal Tumor Research and Treatment
- Neuroblastoma Research and Treatments
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Pediatric Hepatobiliary Diseases and Treatments
- Viral-associated cancers and disorders
- Cancer Diagnosis and Treatment
- Bariatric Surgery and Outcomes
- Genetic factors in colorectal cancer
- Bladder and Urothelial Cancer Treatments
- Infectious Aortic and Vascular Conditions
- Abdominal vascular conditions and treatments
- Liver Disease Diagnosis and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Hepatocellular Carcinoma Treatment and Prognosis
- Extracellular vesicles in disease
Hiroshima University
2017-2025
Hiroshima University Hospital
2021-2023
Hiroshima University of Economics
2023
Fukuoka Kinen Hospital
2014
Asahikawa Medical College Hospital
1997
Pancreatic ductal adenocarcinoma (PDAC) patients with normal carbohydrate antigen (CA) 19-9 levels can have early-stage cancer or advanced without elevation of CA19-9 level; estimating their malignant potential is difficult. This study investigated the clinical utility combined use preoperative CA and Duke pancreatic monoclonal type 2 (DUPAN-2) in PDAC.
Abstract Background Antimicrobial prophylaxis is routinely administered in patients undergoing distal pancreatectomy, with cephalosporins being the most frequently used agents. However, there limited evidence regarding optimal duration of antimicrobial prophylaxis. This study aimed to evaluate pancreatectomy. Methods A multicenter cohort was performed using a common database who underwent pancreatectomy between April 2017 and March 2022 at four high‐volume centers Japan. Eligible were...
Abstract Purpose To elucidate the clinical significance of peritoneal washing cytology (PWC) in patients with resectable biliary tract cancer (BTC). Methods Clinical data BTC, who received PWC at curative intent surgery from March 2009 to December 2021, were retrospectively analyzed. Eligible stratified into two groups according positive or negative PWC. Recurrence-free survival and overall compared between groups. Independent factors associated investigated using multivariate analysis....
Postoperative pancreatic fistula (POPF) continues to be the most common complication after distal pancreatectomy (DP). Recent advancements in surgical techniques have established minimally invasive (MIDP) as standard treatment for various conditions, including cancer. However, MIDP has not demonstrated a clear advantage over open DP terms of POPF rates, indicating need additional strategies prevent MIDP. This trial (WRAP study) aims evaluate efficacy wrapping stump with polyglycolic acid...
Background and Objectives The aim of this study was to investigate the prognostic impact postoperative complications after pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC) stratified by resectability status. Methods Medical records 226 patients with head carcinoma who underwent PD, including 115 resectable (R) 111 borderline resectable/unresectable (BR/UR) PDAC, were reviewed retrospectively. Major defined as grade III or IV based on Clavien‐Dindo classification system....
Abstract Purpose The aim of this study was to assess the validity surgical resection for patients with pancreatic ductal adenocarcinoma (PDAC) aged ≥80 years stratified by resectability status. Methods Medical records 245 resectable (R) and 169 borderline resectable/unresectable (BR/UR) PDAC were reviewed retrospectively. Of total 414 patients, 56 (14%) years. prognostic impact age analyzed stratification Results No significant difference found in incidence major complications between versus...
The aim of this study was to assess whether the duration adjuvant gemcitabine plus S-1 (GS) chemotherapy has any effect on survival in patients with pancreatic ductal adenocarcinoma (PDAC).Of 290 who received GS chemotherapy, 100 (34%) standard (20-29 weeks) and 190 (66%) an extended (≥30 weeks). To reduce selection bias, prognostic impact (recurrence-free [RFS] overall [OS]) based analyzed using inverse probability treatment weighting (IPTW). Moreover, immortal time time-dependent...